RE: WHO press conference23 Jul 2020 16:49
Nolupus - See extract for 1st June RNS
'Part II of the MATINS study has begun and the Company is pleased that patient recruitment continues to be strong, despite the COVID-19 pandemic. This Part II now contains cohorts of nine different cancers at 1.0 mg/kg dosing and three colorectal cancer (CRC) cohorts at 0.3, 1.0 and 3.0 mg/kg. Of these, the 0.3 mg/kg cohort has already recruited, with the additional two CRC cohorts expected to be recruited by mid-summer 2020. The Company intends to present data from these test cohorts (10 patients at each dosing levels) to the FDA at the end-of-phase II meeting to obtain advice ahead of expansion into the pivotal Part III stage of the trial.'
An update relating to the above would be nice!